ProPhase Labs (NASDAQ:PRPH) Share Price Crosses Below 200 Day Moving Average – Here’s What Happened

ProPhase Labs, Inc. (NASDAQ:PRPH)’s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.61 and traded as low as $0.0750. ProPhase Labs shares last traded at $0.0801, with a volume of 45,564 shares changing hands.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of ProPhase Labs to a “hold” rating in a research report on Saturday, December 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

ProPhase Labs Stock Down 10.2%

The firm has a market cap of $486,577.60, a price-to-earnings ratio of -0.02 and a beta of -0.33. The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.14 and a current ratio of 0.14. The business’s 50-day moving average is $0.13 and its 200-day moving average is $1.57.

Institutional Investors Weigh In On ProPhase Labs

A number of hedge funds have recently made changes to their positions in the company. Apollon Wealth Management LLC acquired a new stake in ProPhase Labs in the 3rd quarter valued at about $84,000. Susquehanna International Group LLP increased its position in ProPhase Labs by 290.1% in the 3rd quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock valued at $182,000 after acquiring an additional 295,899 shares in the last quarter. XTX Topco Ltd acquired a new stake in ProPhase Labs in the 2nd quarter valued at about $40,000. Finally, Accretive Wealth Partners LLC acquired a new stake in ProPhase Labs in the 3rd quarter valued at about $114,000. Institutional investors and hedge funds own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.